The abstract is read at the publisher; the summary is JClub's.
In the NeoTRIPaPDL1 trial (280 high-risk triple-negative breast cancer patients), absence of tumor cells in early on-treatment biopsies strongly predicts surgical pathologic complete response in both treatment arms.
- Why it matters: Only a subset of TNBC patients benefits from adding immune checkpoint inhibition to neoadjuvant chemotherapy, and reliable predictive biomarkers are still missing.
- What they did: Tumor biopsies were collected at baseline and on D1C2, followed by longitudinal RNA sequencing of hallmark, immune, and ferroptosis-related signatures; pCR associations were tested with univariable logistic regression and multivariable XGBoost.
- The result: Treatment induced reduced proliferation with increased immune and stromal programs, more pronounced in pCR, and immune-related correlates dominated on-treatment prediction, supporting response-adapted neoadjuvant strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- 1 cited this week
- Open access